CyCa Oncosolutions

Delaware City, United States Founded: 2017 • Age: 9 yrs
Proprietary drug delivery technology for cancer treatment is developed.
Annual revenue $184,685 Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors - Known backers
Products - Services tracked
Competitors 11 Brand Intelligence

About CyCa Oncosolutions

CyCa Oncosolutions is a company based in Delaware City (United States) founded in 2017 by Taiyyaba Kausar and Saikh Fazlul Haque Krishnan. CyCa Oncosolutions operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.

  • Headquarter Delaware City, United States
  • Founders Taiyyaba Kausar, Saikh Fazlul Haque Krishnan
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Cygenica Private Limited
  • Date of Incorporation 28 Feb, 2017
  • Jurisdiction Baleshwar, Orissa, India
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $184.68 K (USD)
    5.97
    as on Mar 31, 2023
  • Net Profit
    $22.07 K (USD)
    -2.55
    as on Mar 31, 2023
  • EBITDA
    $10.21 K (USD)
    -55.67
    as on Mar 31, 2023
  • Latest Funding Round
    Not available
  • Investors
    Not available
  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of CyCa Oncosolutions

Premium access

Detailed funding history for CyCa Oncosolutions

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by CyCa Oncosolutions

Investments
Premium access

Investment portfolio details for CyCa Oncosolutions

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - CyCa Oncosolutions

Premium access

Detailed financials for CyCa Oncosolutions

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Cyca Oncosolutions Comparisons

CyCa Oncosolutions Primary company
Description
Proprietary drug delivery technology for cancer treatment is...
Location
Delaware City, United States
Founded Year
2017
Annual Revenue
$184.68 K (USD)
Net Profit
$22.07 K (USD)
EBITDA
$10.21 K (USD)
Employees
Not available
Premium access

Peer comparison for CyCa Oncosolutions

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of CyCa Oncosolutions

CyCa Oncosolutions operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Antibody-siRNA complexes are developed for cancer treatment.
Locked Locked Locked
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
Locked Locked Locked
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
Locked Locked Locked
Developing novel drugs based on a proteome-wide ligand and target discovery platform
Locked Locked Locked
Dental implants and regenerative dentistry products are developed.
Locked Locked Locked
RNA-editing technologies are provided for precision medicine applications.
Premium access

Detailed competitors of CyCa Oncosolutions

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Cyca Oncosolutions

Premium access

Complete news archive for CyCa Oncosolutions

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about CyCa Oncosolutions

CyCa Oncosolutions was founded in 2017.

CyCa Oncosolutions is headquartered in Delaware City, United States. It is registered at Delaware City, Delaware, United States.

Annual revenue of CyCa Oncosolutions is $184.68K as on Mar 31, 2023.

CyCa OncoSolutions was founded in 2017 in Delaware City, United States, and operates in the life sciences sector. Drug delivery technology is provided to industry partners through a proprietary non-endocytic cell entry mechanism. Higher cellular uptake is achieved with lower dosages and fewer side effects, according to company claims. Primary application is targeted toward cancer cells.

CyCa Oncosolutions's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available